Semma Therapeutics

What Semma Therapeutics does

Semma Therapeutics was a Cambridge, Massachusetts-based clinical-stage biotechnology company founded in 2014 to develop transformative cell therapies for Type 1 diabetes patients. The company's core technology centered on induced pluripotent stem cell (iPSC)-derived cell therapeutics, with the goal of generating functional insulin-producing beta cells that could restore endogenous insulin production in T1D patients. Semma was co-founded by Douglas Melton, a leading Harvard stem cell biologist, and assembled a leadership team including a CFO and Chief Medical Officer with pharmaceutical development experience. The company pursued a vertically integrated cell therapy platform, as evidenced by its 2015 acquisition of CytoSolv, which strengthened its cell delivery and encapsulation capabilities.

Semma's business model was that of a pre-commercial, clinical-stage biotech: it raised approximately $163 million in equity financing across 2014-2017 from a high-quality syndicate that included ARCH Venture Partners, F-Prime, MPM Capital, Novartis, Medtronic, JDRF T1D Fund, and Eight Roads Ventures, and monetized its value through eventual acquisition rather than product sales. In 2019, Semma was acquired by Vertex Pharmaceuticals for approximately $950 million as a strategic move to build Vertex's cell and genetic therapy capabilities, particularly for Type 1 diabetes. Following the acquisition, Semma operates as a wholly-owned subsidiary of Vertex Pharmaceuticals, and its iPSC-derived cell therapy platform has been integrated into Vertex's broader pipeline that spans cystic fibrosis, sickle cell disease, beta thalassemia, kidney diseases, pain, and Type 1 diabetes.

Semma had no commercial products or revenue at the time of acquisition, and its customer base was prospective — Type 1 diabetes patients — rather than active paying customers. The company served as a focused platform play within the broader pharmaceutical value chain, with its clinical and commercial development now conducted under Vertex's global R&D and commercial infrastructure spanning the United States, Canada, the United Kingdom, France, Germany, Italy, Spain, Australia, and the Middle East (GCC region).

Name

Semma Therapeutics

Legal name

Semma Therapeutics

Website

https://semma-tx.com

Company type

Private

Founded year

2014

Operating status

Acquired

Headcount range

51–100 employees

Short description

Semma Therapeutics was a clinical-stage biotech founded in 2014 that developed iPSC-derived cell therapeutics to treat Type 1 diabetes, acquired by Vertex Pharmaceuticals in 2019 for approximately $950 million to serve as Vertex's cell therapy platform.

Ownership category

akta.pro rank

Product category

Cell Therapy Pharmaceuticals

akta.pro primary industry

Cell Therapy Developers (Autologous) (HLAAABAA)

akta.pro secondary industries

Type 1 Diabetes Care (HLAKADAB), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

Keywords

• Cell therapy diabetes
• IPSC derived therapeutics
• Stem cell therapy
• Regenerative medicine
• Type 1 diabetes treatment

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices10 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain

Revenue model

1. Prescription pharmaceutical products: Vertex generates revenue through sales of FDA-approved prescription medicines including cystic fibrosis treatments, CRISPR-based therapies, and pipeline candidates. Revenue is derived from both commercialized products and potential future approvals.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

Semma Therapeutics develops transformative cell-based therapies for Type 1 diabetes patients using proprietary iPSC-derived cell therapeutics. The company focuses on engineering stem cell-derived islet cells capable of producing insulin as a regenerative approach to insulin-dependent diabetes. Now operating as a wholly-owned subsidiary of Vertex Pharmaceuticals, Semma's platform contributes cell therapy capabilities to Vertex's broader cell and genetic therapy portfolio.

Differentiator

Problem solved

Functional benefit

Products and services

• Cell Therapy for Type 1 Diabetes Cell-based therapy derived from induced pluripotent stem cells (iPSC) for the treatment of Type 1 diabetes, designed to provide insulin-producing islet cells as a regenerative treatment for patients with insulin-dependent diabetes. Developed for patients with serious metabolic disease with significant unmet medical need.

Quantifiable outcome

• CASGEVY approved for sickle cell disease and beta thalassemia
• +1 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and major.

• Semma TherapeuticscoreStrategic or Co-development Partner · 1 January 2019Vertex acquired Semma Therapeutics for approximately $950 million to build cell therapy capabilities, particularly for the development of treatments for type 1 diabetes using iPSC-derived cell therapeutics.
• CRISPR TherapeuticscoreStrategic or Co-development PartnerVertex partnered with CRISPR Therapeutics for the development and commercialization of CRISPR-based gene editing therapies. This partnership resulted in CASGEVY (exagamglogene autotemcel), the first FDA-approved CRISPR gene-edited therapy for sickle cell disease and beta thalassemia.
• Moderna TherapeuticsmajorStrategic or Co-development PartnerVertex has a partnership with Moderna Therapeutics for the development of certain therapies leveraging Moderna's mRNA technology platform.
• Exonics TherapeuticscoreStrategic or Co-development PartnerVertex acquired Exonics Therapeutics to build genetic therapy capabilities, particularly for the development of gene editing therapies for serious diseases.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• ViaCyte: ViaCyte is the most direct peer, developing stem cell-derived islet cell replacement therapies for Type 1 diabetes using encapsulated cell approaches. It is the clearest head-to-head competitor to Semma's iPSC-derived beta cell program and targets the same patient population.
• BlueRock Therapeutics: BlueRock Therapeutics (acquired by Bayer) develops iPSC-derived cell therapies, including for diabetes. It is a direct peer in the iPSC-derived cell therapy category and competes with Semma for talent, capital, and clinical milestones.

Broad incumbents

• Vertex Pharmaceuticals: Vertex is Semma's parent company and the acquirer of its T1D program. Vertex is a broad incumbent in serious-disease therapeutics (cystic fibrosis, sickle cell, beta thalassemia) and now owns the Semma T1D cell therapy assets, making it both a stakeholder and a downstream competitor in the T1D space.
• Eli Lilly: Eli Lilly is the largest incumbent in T1D via insulins, CGMs, pumps, and emerging cell-therapy collaborations. It defines the standard-of-care competitive landscape that any Semma-derived therapy must displace and is also developing its own cell-based approaches.
• Novo Nordisk: Novo Nordisk is the global leader in insulin therapy and a major incumbent in T1D standard-of-care. It competes with any curative T1D cell therapy on installed-base economics and could itself enter cell therapy, making it a strategic peer for Semma's downstream market.
• Medtronic: Medtronic is an investor in Semma and the global leader in insulin pumps and automated insulin delivery systems for T1D. It is a broad incumbent in T1D management whose installed base of pump users competes with curative cell therapy for the same patient population.

Emerging players

• CRISPR Therapeutics: CRISPR Therapeutics partnered with Vertex to develop CASGEVY and holds gene-editing capabilities that could be combined with Semma's iPSC platform to produce hypoimmune beta cells. It is an enabling strategic peer in the cell-and-gene-therapy convergence for T1D.
• Sana Biotechnology: Sana Biotechnology is a cell therapy platform company working on hypoimmune allogeneic cells and stem cell-derived therapies. Its scientific approach overlaps with Semma's iPSC-derived beta cell strategy and positions it as a potential competitor for cell-replacement indications including T1D.
• Sigilon Therapeutics: Sigilon developed encapsulated cell therapies for Type 1 diabetes using stem cell-derived beta cells. It pursued a comparable scientific approach to Semma and represents a direct albeit smaller-scale competitor in T1D cell replacement.
• Moderna Therapeutics: Moderna is a Vertex partner leveraging mRNA technology and is also pursuing cell-therapy-adjacent and immuno-modulatory approaches. It represents an alternative platform modality that could compete for T1D patients via different mechanisms (e.g., immune tolerance).

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/semmatx

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds5 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Semma Therapeutics